Table 2.
Tenascin-X immunostaining results
| Diagnosis | Tenascin-X staining extent | ||||
|---|---|---|---|---|---|
| 0% | 1–5% | 6–25% | 26–75% | 76–100% | |
| Effusions (174) | |||||
| Breast carcinoma (52) | 36 (9%) | 13 (25%) | 2 (4%) | 1 (2%) | 0 (0%) |
| Ovarian carcinoma a (47) | 42 (89%) | 4 (9%) | 1 (2%) | 0 (0%) | 0 (0%) |
| Malignant mesothelioma (37) | 3 (8%) | 6 (16%) | 4 (11% | 15 (41%) | 9 (24%) |
| Other gynecological carcinomas b (15) | 11(73%) | 4 (27%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Lung carcinoma (12) | 10 (83%) | 2 (17%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gastrointestinal carcinomas c (10) | 6 (60%) | 4 (40%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Reactive (9) | 6 (67%) | 2 (22%) | 1 (11%) | 0 (0%) | 0 (0%) |
| Prostate carcinoma (1) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Solid tumors (178) | |||||
| Ovarian carcinoma d (122) | 122 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Malignant mesothelioma (56) | 15 (27%) | 22 (39%) | 12 (21%) | 7 (13%) | 0 (0%) |
a
Including 42 ovarian carcinomas and 5 primary peritoneal carcinomas
b
5 uterine cervical and 10 endometrial carcinomas.
c
5 esophageal, 1 colon, 3 gastric and 1 pancreatic carcinoma.
d
42 primary carcinomas, 80 metastases.